

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Bubendorf, September 23, 2021

Ad hoc announcement pursuant to Art. 53 LR of the Swiss stock exchange SIX

Bachem intends a capital increase to accelerate capacity expansion and construction of an additional manufacturing site in Switzerland

- Call for an Extraordinary General Meeting on October 15, 2021, to create additional authorized share capital.
- Authorization of up to 1 million new shares, representing ca. 7% of currently issued share capital.
- Capital to be used to finance investments in capacity expansion, including an additional manufacturing site in Switzerland.
- Upon completion the capital increase will enhance the trading liquidity of Bachem shares and expand the shareholder base.

Bachem (SIX: BANB) announced today that it is calling for an Extraordinary General Meeting in order to create the grounds for strengthening the company's capital base for investments into sustainable growth. The Board of Directors therefore proposes the creation of up to one million new shares through an authorized capital increase.

Bachem is the world market leader for peptides with fifty years of experience in the manufacturing and development of these specialized molecules, which are used as an active pharmaceutical ingredient in a number of medicines. The company intends to further expand its leadership position in a rapidly growing peptide market and to become a leading provider of oligonucleotides, a new therapeutic platform on the basis of DNA or RNA. Bachem is a key contributor to the global supply with innovative medicines and is pursuing a sustainable strategy of profitable growth.

In view of promising long-term growth prospects, Bachem intends to accelerate the expansion of its capacity across all its sites and business areas. In the next five years the company plans investments of over CHF 500 million.

Bachem is investing in the construction of the company's hitherto largest manufacturing facility in Bubendorf, the expansion of automated manufacturing solutions, equipment and technology across all its sites, as well as the establishment of an additional manufacturing site. A site search within Switzerland is ongoing.

With the aim of increasing the trading liquidity of Bachem shares and broaden the shareholder base, Peter Grogg will not participate in the anticipated capital increase. Peter Grogg, founder

and honorary president, as well as further family members, will continue to hold a majority of the share capital and reaffirm their existing long-term commitment to Bachem. Further details of the capital raising will be announced in due course.

UBS and Zürcher Kantonalbank were mandated to advise on the structuring and implementation of the capital increase.

An investor presentation is available under <https://www.bachem.com/about-bachem/investors-and-media/reports-and-presentations/>.

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.

Bachem celebrates fifty years of company history. From Peter Grogg's business idea in the 1970s to the world's leading company in the development and production of peptides and oligonucleotides. A success story based on courage, innovation, quality, partnership, and unique people.

50 Years Bachem

For more information:

Bachem Holding AG
Dr. Daniel Grotzky
Head Group Communications
Tel.: +41 58 595 2021

Media: media@bachem.com

Investors: ir@bachem.com

Disclaimer:

This document is not an offer to sell or a solicitation of offers to purchase or subscribe for shares. This document is not a prospectus within the meaning of the Swiss Financial Services Act and not a prospectus under any other applicable laws. Copies of this document may not be sent to, distributed in or sent from jurisdictions in which this is barred or prohibited by law. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction.

This document is not for publication or distribution in the United States of America (including its territories and possessions, any State of the United States and the District of Columbia), Canada, Japan or Australia or any other jurisdiction into which the same would be unlawful. This document does not constitute an offer or invitation to subscribe for or purchase any securities in such countries or in any other jurisdiction into which the same would be unlawful. In particular, the document and the information contained herein should not be distributed or otherwise transmitted into the United States of America or to publications with a general circulation in the United States of America. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or the laws of any state and may not be offered or sold in the United States of America absent registration under or an exemption from registration under the Securities Act. There will be no public offering of the securities in the United States of America.

The information contained herein does not constitute an offer of securities to the public in the United Kingdom. No prospectus offering securities to the public will be published in the United Kingdom. In the United Kingdom this document is only directed at persons who (i) are "qualified investors" within the meaning of Article 2 of Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 and who are also (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FSMA Order"); (iii) persons falling within Articles 49(2)(a) to (d), "high net worth companies, unincorporated associations, etc." of the FSMA Order and (iv) persons to whom an invitation or inducement to engage in investment activity within the meaning of Section 21 of the Financial Services and Markets Act 2000 may otherwise be lawfully communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). The securities are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

In any member state of the European Economic Area (each a "Relevant State") this document is only addressed to qualified investors in that Relevant State within the meaning of the Prospectus Regulation.

This publication may contain specific forward-looking statements, e.g. statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual

results, financial situation, development or performance of Bachem Holding AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Bachem Holding AG assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments.

Except as required by applicable law, Bachem Holding AG has no intention or obligation to update, keep updated or revise this publication or any parts thereof following the date hereof.